Discriminating Between the Roles of Androgens and Estrogens in Cardiovascular Disease by Panagiota Manolakou et al.
457
should be, directly or indirectly, responsible3. Initially, 
however, only the supposedly benefi cial effect of estrogens 
was taken into consideration. A more attentive inquiry 
into the distribution of cardiovascular events across vari-
ous age groups failed to support this common belief. For 
instance, it is clearly evident that cardiovascular event 
rates are not affected by the onset of menopause, in the 
same way that other estrogen-dependent conditions are. 
In support of the latter case one might compare cardiovas-
cular events to breast cancer death rates, whereby it be-
comes evident that there seems to be no threshold value 
for increased cardiovascular event incidence, refl ecting 
the sudden deprival from estrogens that occurs in meno-
pause4 (Figure 1). On the contrary, the overall curve for 
cardiovascular deaths in women seems very similar to 
that in men with the sole exception of a fi ve to ten years’ 
period of delay4,5 (Figure 2).
Given these observations, scientifi c interest slowly be-
gan to turn towards the, up until recently mostly neglect-
ed, androgens. An inspection of various prospective stud-
ies has shown that there seems to be no correlation 
between endogenous testosterone levels and adverse car-
diovascular outcomes5. On the contrary, observational 
studies insist that men with a history of cardiovascular 
Cardiovascular episodes comprise an important cause 
of disability and mortality among adults. As such, they 
have been carefully observed and studied since the ancient 
times. The oldest description in fact dates back to 2000 
years ago and has been attributed to Seneca, who gave a 
written account of a myocardial ischemia episode. Natu-
rally, a lot has changed since that fi rst account, but the 
anthropological and medical interest remains continu-
ously high. One of the most notable observations made in 
relation to this fi eld is the fact that sex seems to constitute 
a major risk factor, although the mechanism of this dimor-
phic effect is unclear.
Androgens versus Estrogens: 
Which One Should We Blame?
It is a well established fact that cardiovascular deaths 
show a predominantly higher rate in men than in women, 
a difference that remains consistent across 52 countries, 
despite a wide variety of environmental and socio-econom-
ic diversities1. Since this sex-specifi c protection of women 
persists, even after adjusting for any known risk factors, 
it was only natural to assume that, like with most other 
aspects of sexual dimorphism2, androgens and estrogens 
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A B S T R A C T
Cardiovascular disease shows a distinct difference in incidence rates between men and women, a fact that has been 
known for many years. While initial theories supported that this could be attributed to the protective effect of estrogens in 
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sclerosis-related indexes indicate otherwise. Similarly, endogenous androgen levels seem to correlate with opposite effects 
in males and females, whereas exogenous treatment with either androgens or estrogens fails to correspond to scientifi c 
expectations entirely. A brief discussion of the merits and pitfalls of placing either estrogens or androgens alone at the root 
of the problem shows that current understanding is inadequate concerning this major anthropological issue, as it refers 
to the primary global mortality and morbidity cause.
Key words: androgens, estrogens, sex, cardiovascular disease, atherosclerosis, cardiovascular risk factors
Introduction
Received for publication May 28, 2010
458
P. Manolakou et al.: Androgens and Estrogens in Cardiovascular Disease, Coll. Antropol. 39 (2015) 2: 457–460
disease tend to display lower endogenous testosterone lev-
els6. While this might be interpreted as a common result 
of many chronic disorders, the nature of this relationship 
remains unclear7.
Furthermore, androgens seem to have a complex rela-
tionship with several proven risk factors for coronary 
heart disease (CHD). More interestingly, endogenous tes-
tosterone levels appear to have opposite effects in men and 
women, with regard to cardiovascular protection5. In par-
ticular, circulating testosterone levels have been positive-
ly correlated with HDL-C and inversely correlated with 
LDL-C, fi brinogen and plasminogen activator type 1 (PAI-
1) serum levels in men. These inverse correlations seem 
to extend to body mass index, waist circumference, waist-
to-hip ratio, amount of visceral fat and leptin, insulin and 
free fatty acid levels to a degree that can account for the 
above. However, in women, circulating testosterone dis-
plays a precisely opposite profi le, barring us from reaching 
any defi nite conclusions as to the role that androgens may 
play in the progression of cardiovascular disease.
On the other hand, although more consistent in their 
behavior, estrogens do not seem to correspond to the role 
originally supposed for them either. Circulating estrogen 
levels seem to contribute towards a less favorable lipid 
profi le in women8,9 and the progression of atherosclerosis 
in men10, as opposed to what one may have expected. Thus, 
the exact contribution of each type of sex steroids in car-
diovascular disease progression remains debatable.
Estrogens: the HRT Paradox
Since its conception, hormone replacement therapy 
(HRT) was meant to prolong the protective effects of es-
trogens in women past the onset of menopause. Initially, 
this was considered to apply to the cardiovascular system 
as well. However, with the implementation of the fi rst ran-
domized controlled trials of its effects on cardiovascular 
disease rates, it became apparent that HRT was hardly 
as benefi cial as clinicians had expected it (and hoped) to 
be. One particular trial showed an increase in acute coro-
nary events among women with ischemic heart disease 
that underwent HRT11, thus challenging the effects of 
HRT on women with an already present cardiovascular 
history. Subsequently, the Women’s Health Initiative 
(WHI) randomized controlled trial showed an increase in 
CHD events and strokes among healthy women receiving 
HRT12. While this sort of evidence has yet to evict HRT 
from its current therapeutic indication for post-menopaus-
al women, it has already been established that certain 
patient groups might benefi t more by refraining from it, 
at least until the matter has been properly resolved.
Then again, if that is the case, then what prompted the 
initial popularity with which HRT was greeted? Looking 
back, an explanation seems to lie in the fact that this par-
ticular hypothesis was initially supported by case-control 
observational studies that reported lower cardiovascular 
event rates among women receiving HRT. A major limita-
tion, however, is that those initial studies most likely ig-
nored the selective recruitment of healthier and wealthier 
women that could afford and were more likely to be well-
enough informed in order to require about or receive 
HRT3. This detail highlights the importance of designing 
and implementing well-structured, randomized trials be-
fore establishing therapeutic policies.
As a matter of fact, the deleterious effects of estrogens 
on the cardiovascular system had already been long 
known with regard to their administration to men, since 
observational data made among prostate cancer patients 
treated with estrogens date back to the 1960s13. In other 
words, it becomes apparent that exogenous administration 
of estrogens fails to meet therapeutic expectations and 
seems in fact to bring about the opposite effect on both 
sexes.
Fig. 1. Cardiovascular and breast cancer mortality rates on a 
logarithmic scale. Estrogen-dependent conditions, such as breast 
cancer, display a breaking point in mortality in the age group that 
corresponds to menopause, due to sudden estrogen deprivation. 
Cardiovascular mortality, however, fails to display any such 
changes, a fact that advocates against estrogens being the under-
lying mechanism for the differences in cardiovascular disease 
incidence between the two sexes. (Redrawn from the work of Liu2).
Fig. 2. Incidence of annual coronary deaths on a linear scale. The 
curve for coronary deaths in women is almost identical to that for 
men, with the sole exception of a fi ve to ten years’ worth of delay. 
Coronary deaths in women equal and then surpass those in men 
in later age groups. (Redrawn from the work of Tunstall-Pedoe3).
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Androgens: Special Population Groups
While estrogen treatment has become more common-
place with the form of hormone replacement treatment, 
there are certain limitations in the study of the effects of 
artifi cially altered androgen levels. For this purpose, spe-
cial population groups have been used in the past. These 
included normal men after castration3, female-to-male 
(F2M) transsexuals that are treated with testosterone3 
and women with polycystic ovaries syndrome (PCOS)5. 
Castrated men, especially those undergoing castration at 
an early age, are consistently exposed to lower levels of 
androgens, while F2M transsexuals and women with 
PCOS are genetically females, but display a constant ex-
posure to androgen excess. In all cases, no adverse andro-
gen effect was found as far as the cardiovascular system 
was concerned. On the contrary, it has been observed that, 
despite the presence of various other risk factors in wom-
en with PCOS, there was no increase in the overall car-
diovascular risk. And even though a few of those other 
factors, namely obesity and insulin resistance, have been 
attributed by some to hyperandrogenemia itself, it has yet 
to be proven that such a relationship exists.
Furthermore, in the light of recent trends, more atten-
tion is being granted to the effects of anabolic steroid 
abuse in sports. Although several case reports of cardio-
vascular complications have been recorded, it has been 
argued that without an estimation of the size of the refer-
ence population that makes use of anabolic steroids we 
cannot speculate about their true incidence rates. For ex-
ample, according to classifi ed documents saved after the 
collapse of the German Democratic Republic (GDR) in 
1990, the Eastern German national sports doping pro-
gram reported a variety of regularly occurring complica-
tions, but no adverse cardiovascular effects14. Besides, we 
cannot ignore the fact that anabolic steroid abuse usually 
involves highly supra-physiological concentrations of syn-
thetic androgens. Still, given the widespread use of such 
substances in the sports world despite our best efforts, it 
will probably prove benefi cial to look into their short-term 
and long-term complications even more carefully, espe-
cially due to the recent revelation of their multiple actions 
in metabolic physiology and reproductive health15–16.
Conclusion
Although the sex-specifi c differences in cardiovascular 
incidence rates have long been known, we are still a long 
way from fully understanding what truly lies beneath. The 
existing studies about the effects of circulating sex ste-
roids, as well as their exogenously treated counterparts, 
have yet to provide any conclusive evidence concerning the 
mechanism underlying sex differentiation in cardiovascu-
lar disease. As such, prompting scientists towards further 
research in this fi eld may yield valuable information in 
the future, allowing anthropologists to comprehend dif-
ferential survival opportunities for existing human popu-
lations.
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RAZLIKOVANJE ULOGA ANDROGENA I ESTROGENA KOD KARDIOVASKULARNIH BOLESTI
S A Ž E T A K
Kardiovaskularne bolesti pokazuju izrazitu razliku u prevalenciji među muškaracima i ženama, što je poznata 
činjenica već dugi niz godina. Dok su početne teorije tvrdile kako se to može pripisati zaštitnom učinku estrogena kod 
žena, povezivanje prirođene razine estrogena s kardiovaskularnim čimbenicima rizika i pokazateljima progresije 
ateroskleroze ukazuju na suprotno. Također, prirođene razine androgena povezuju se sa suprotnim učincima kod 
muškaraca i žena, dok liječenje bilo androgenom ili estrogenom ne odgovara znanstvenim očekivanjima u cijelosti. 
Kratka rasprava o osnovanosti i zamkama liječenjem bilo estrogenom ili androgenom u korijenu problema pokazuje da 
je trenutno razumijevanje neadekvatno u vezi ovog velikog antropološkog pitanja, jer se odnosi na primarni globalni 
uzrok mortaliteta i morbiditeta.
